MoneyWorks4Me

Medicamen Biotech - Quaterly Results

10 Feb 2023 Evaluate
The total revenue for the quarter ended December 2022 remained nearly unchanged at Rs. 341.16 millions.The Company's Net profit for the December 2022 quarter have declined marginally to Rs. 37.60  millions as against Rs. 37.78 millions reported during the corresponding quarter ended.Operating Profit reported a sharp decline to 64.95 millions from 71.36 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 341.16 326.41 4.52 1007.36 926.91 8.68 1154.45 1101.46 4.81
Other Income 6.29 8.27 -23.94 21.16 13.82 53.11 17.20 7.54 128.12
PBIDT 64.95 71.36 -8.98 194.94 199.58 -2.32 252.74 203.35 24.29
Interest 6.82 4.93 38.34 20.65 8.37 146.71 14.01 10.64 31.67
PBDT 58.13 66.43 -12.49 174.29 191.21 -8.85 238.73 192.71 23.88
Depreciation 16.01 15.67 2.17 47.43 42.47 11.68 57.71 25.20 129.01
PBT 42.12 50.76 -17.02 126.86 148.74 -14.71 181.02 167.51 8.07
TAX 4.52 12.98 -65.18 17.29 27.23 -36.50 31.97 42.65 -25.04
Deferred Tax -3.32 -2.54 30.71 -8.95 -7.19 24.48 -7.80 1.19 -755.46
PAT 37.60 37.78 -0.48 109.57 121.51 -9.83 149.05 124.86 19.37
Equity 126.51 122.17 3.55 126.51 122.17 3.55 122.17 122.17 0.00
PBIDTM(%) 19.04 21.86 -12.92 19.35 21.53 -10.13 21.89 18.46 18.58
Peers
Company Name CMP
Sun Pharma. Inds. 1853.00
Dr. Reddys Labs. 1200.40
Cipla 1404.00
Lupin 2098.00
Zydus Lifesciences 1180.00
View more..